Ad hoc announcement pursuant to Art. 53 LR (IN BRIEF) Basilea Pharmaceutica has been awarded USD 6 million by the Biomedical Advanced Research and Development Authority to continue development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Security & Safety, Switzerland
Tagged antibiotic development, antimicrobial resistance, ASPR, BARDA, Basilea Advances Antibiotic Pipeline with BARDA Funding for Oral Beta Lactam Combination Therapy, Basilea Pharmaceutica, Basilea Receives USD 6 Million BARDA Funding to Advance Development of Oral Antibiotic for Drug Resistant Urinary Infections, beta lactam beta lactamase inhibitor, ceftibuten ledaborbactam etzadroxil, complicated urinary tract infections cUTI, Cresemba®, David Veitch, FDA Fast Track designation, multidrug resistant bacteria, pyelonephritis, Qualified Infectious Disease Product QIDP, US Department of Health and Human Services, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has initiated FORWARD‑IM, a global Phase 3 trial evaluating fosmanogepix in adults with invasive mold infections. Building on positive Phase 1 and Phase 2 results—and following the FAST‑IC Phase 3 candidemia trial—this open‑label study will randomize about 160 patients to … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Amplyx Pharmaceuticals, Aspergillus spp., BARDA, Basilea Pharmaceutica Ltd, broad‑spectrum antifungal, Candida auris, candidemia, Cresemba®, FAST‑IC, FDA Fast Track, FORWARD‑IM, fosmanogepix, Fusarium spp., HHS ASPR, invasive candidiasis, invasive mold infections, Lomentospora prolificans, Mucorales, orphan drug, Pfizer, phase 3 study, PSI CRO AG, QIDP, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has secured an extra USD 39 million from BARDA under its Other Transaction Agreement, bringing potential non-dilutive funding to USD 268 million over 12 years. This new tranche will finance the ongoing phase 3 trial of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Allschwil, antibacterial, antifungal, ASPR, BAL2062, BARDA, Basilea Pharmaceutica Ltd, Cresemba®, fosmanogepix, HHS, invasive candidiasis, invasive mold infections, multidrug-resistant Candida auris, orphan drug, Other Transaction Agreement, partnership, QIDP, Switzerland, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AKP, antifungal treatment, Asahi Kasei Pharma, aspergillosis, azole antifungal, Basilea Pharmaceutica, biopharmaceuticals, branded antifungal leader, Cresemba®, cryptococcosis, David Veitch, fungal infection therapies, global antifungal sales, intravenous antifungal, invasive fungal infections, Isavuconazole, Japan pharmaceutical market, Japanese drug market, milestone payment, mucormycosis, oral antifungal, partnership
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), achieved significant sales in Europe, triggering a USD 25 million milestone payment from partner Pfizer. This achievement highlights Cresemba’s strong performance in treating severe fungal infections. The milestone … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Basilea Pharmaceutica, Cresemba®, David Veitch, Financial, fungal infections, investment
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) announced a significant milestone with a USD 1.25 million payment triggered by the robust sales performance of its antifungal medication, Cresemba® (isavuconazole), in the Asia Pacific region and China by its license partner … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Security & Safety, Switzerland, Technology
Tagged Asia Pacific, Basilea Pharmaceutica, CHINA, Cresemba®, David Veitch, Financial, investment
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales threshold for the antifungal Cresemba (isavuconazole) in Latin America in 2023, triggering the first sales milestone payment for the region. … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antifungal, Basilea, Cresemba®, David Veitch, Knight Therapeutics, Latin America, partnership, sustainability
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company dedicated to addressing severe bacterial and fungal infections, has announced that its antifungal medication, Cresemba® (isavuconazole), has achieved robust sales performance in the Asia Pacific region and China through its licensing partner, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Antifungal Drug, Asia Pacific, Basilea, Cresemba®, David Veitch, partnership, Pfizer Inc.
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial results for the first half-year ending June 30, 2023. Their CEO, David Veitch, highlighted the company’s progress in executing their … Read the full press release
Posted in Business, Financial, Healthcare, Management, Marketing, News, Pharma & Biotech, Science, Switzerland
Tagged Adesh Kaul, Basilea Pharmaceutica, Cresemba®, David Veitch, financial results, Zevtera®
BASEL, 11-Dec-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) by Astellas Pharma Inc. (“Astellas”) in the United States exceeded the threshold triggering a milestone payment to Basilea in the amount of … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged antifungal, aspergillosis, Astellas, Basilea, Cresemba®, Isavuconazole, mucormycosis
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?